We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £655,011
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
Flat Cap Hotels (FCH) own and operate hotels, restaurants, bars and pubs. They specialise in locally sourced British menus and homely accomodation. FCH currently own two establishments; The Vicarage and The Courthouse.
days to go: Expired investment: £170,030
Yapa® is a free social app with an emphasis on your mental health. The application gives a solution to the users to have accurate changes in both mental illness and mental wellness. The application has exceeded 10,000 downloads, and it has 400,000 followers. It has elected former England and Liverpool FC goalkeeper Chris Kirkland as the first ambassador to encourage and build Yapa. The funds will be used for marketing, operation and product innovation.
days to go: Expired investment: £41,930
Movem is a platform where tenants, landlords and agencies have been sharing their rental experiences since 2013. Building a digital rental profile known as a Movem Passport. Landlords and agents can pay to instantly download a tenant's full reference, designed to be quicker, cheaper and less open to fraud.
days to go: Expired investment: £395,580
E-RIDER sell electric bikes and scooters and is a new concept in personal travel. The E-RIDER bikes and scooters glide over the road with all the convenience of a silent motorcycle. All of the E-RIDER bikes and scooters come with a brake light, audible indicators, wing mirrors and motorbike suspension and these all allow for a more comfortable, safer ride.
days to go: Expired investment: £4,550
Healing clouds is an online platform that connects holistic health practitions with various modalities such as reiki, theta healing, pranic healing and many more. They offer holistic healing globally through live and secure video sessions. EIS (pending) SEIS (pending)
days to go: Expired investment: £122,080
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph